We’re proud of the value we create for all our stakeholders, and strive to communicate our performance in a clear and timely manner. Download the latest reports, or stay up to date on various metrics of our market performance here. If you have any queries not addressed here, please feel free to get in touch with Investor Relations on our Contact page.
Observe Medical ASA was listed on Oslo Børs 4 November 2019. Our ambition is to provide shareholders, analysts and investors simultaneous access to accurate, clear and relevant information. We aim to make all our communication to the financial market available on this web site.
FINANCIAL YEAR 2021 03.11.2021 – Quarterly Presentation – Q3 17.02.2022 – Quarterly Presentation – Q4 29.04.2022 – Annual Report 02.06.2022 – Annual General Meeting FINANCIAL YEAR 2022 12.05.2022 – Quarterly Presentation – Q1 25.08.2022 – Second quarter and Half-year Report 03.11.2022 – Quarterly Report – Q3 This information is published pursuant to the requirements set out…
Read moreOslo, August 20[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the second quarter and first half-year of 2021, reporting continuous progress in the go-to-market execution for Sippi®, a unique and proprietary solution for digital, automated urine monitoring. “We have a sharp focus on continuous roll-out of Sippi®,…
Read moreObserve Medical ASA invites you to a presentation of the second quarter and first half year 2021. The presentation will take place at Felix Konferansesenter in Oslo on Friday, August 20th. The event will start at 08.30 CET and will be webcasted live on www.observemedical.com – Investor relations and at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20210820_3/ …
Read moreAnnual Report
Quarterly Presentation - Q1
Annual General Meeting
Half-yearly Report
Quarterly Presentation - Q3
Last updated 4 October 2021
| Name | Number of shares | % of top 20 | % of total | Country | |
|---|---|---|---|---|---|
| 1 | NAVAMEDIC ASA | 4,222,727 | 25.12% | 21.54% | Norway |
| 2 | INGERØ REITEN INV. COMPANY AS | 3,939,394 | 23.43% | 20.09% | Norway |
| 3 | RO, LARS | 1,501,051 | 8.93% | 7.66% | NORWAY |
| 4 | UBS SWITZERLAND AG | 1,418,522 | 8.44% | 7.24% | SWITZERLAND |
| 5 | ARTAL AS | 1,064,457 | 6.33% | 5.43% | Norway |
| 6 | ALPINE CAPITAL AS | 745,446 | 4.43% | 3.80% | Norway |
| 7 | Soleglad Invest AS | 586,668 | 3.49% | 2.99% | NORWAY |
| 8 | NORDA ASA | 511,632 | 3.04% | 2.61% | NORWAY |
| 9 | TRANBERGKOLLEN INVEST AS | 500,000 | 2.97% | 2.55% | Norway |
| 10 | LEIKERANE AS | 373,439 | 2.22% | 1.90% | Norway |
| 11 | LAPAS AS | 348,326 | 2.07% | 1.78% | Norway |
| 12 | GINNY INVEST AS | 270,030 | 1.61% | 1.38% | NORWAY |
| 13 | PHILIP HOLDING AS | 260,000 | 1.55% | 1.33% | NORWAY |
| 14 | KRAEBER VERWALTUNG GMBH | 214,850 | 1.28% | 1.10% | GERMANY |
| 15 | cam as | 181,000 | 1.08% | 0.92% | NORWAY |
| 16 | mp pENSJON PK | 176,135 | 1.05% | 0.90% | NORWAY |
| 17 | NORDNET BANK AB | 138,618 | 0.82% | 0.71% | SWEDEN |
| 18 | BJØRNTVEDT, VEGARD | 123,253 | 0.73% | 0.63% | NORWAY |
| 19 | ABC INVEST AS | 120,000 | 0.71% | 0.61% | NORWAY |
| 20 | EILERAAS, KARL ANSKAR | 115,013 | 0.68% | 0.59% | Norway |
| Total numBer owned by top 20 | 16,810,561 | 100.00% | 85.74% | ||
| Total number of shares | 19,605,457 |
Stock Exchange:
Ticker:
First day of listing:
Sector:
Trading Currency:
ISIN:
Number of shares issued:
Nominal value:
Euronext Expand Oslo
OBSRV
4 November 2019
Healthcare
NOK
NO0010865009
19 605 457
NOK 0.26
21 May 2021: Minutes from Annual General meeting
30 April 2021: Notice of Annual General Meeting on 21 May 2021
30 April 2021: Notice of attendance and proxy form to the Annual General meeting on 21 May 2021
30 April 2021: The Nomination Committee's recommendation
30 April 2021: Guidelines for determination of salary and other remuneration to executive Personnel
30 June 2020: Annual General Meeting
16 June 2020: Extraordinary General Meeting
9 June 2020: Notice of Annual General Meeting on 30 June 2020
9 June 2020: Attendance to the Annual General Meeting on 30 June 2020
9 June 2020: Recommendation by the Nomination Committee
9 June 2020: The Boards declaration on remuneration to executive management
26 May 2020: Notice of Extraordinary General Meeting on 16 June 2020
26 May 2020: Attendance to the Extraordinary General Meeting on 16 June 2020
24 October 2019: Extraordinary General Meeting
1 October 2019: Extraordinary General Meeting
5 August 2019: Extraordinary General Meeting
The Articles of Association provide for a nomination committee composed of two or three members. The current members of the nomination committee are Bård Brath Ingerø (chair) and Grete Hogstad.
The nomination committee is responsible for nominating candidates for the election of shareholder-elected members and chairperson to the Board of Directors and for nominating members to the nomination committee, as well as making recommendations for remuneration of these.
For nomination committee please contact:
Bård Brath Ingerø, Chair of the Nomination Committee
+47 92 83 33 34 / bbi@reitenco.no